These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 8644760

  • 21. [Visceral leishmaniasis: new drugs].
    Minodier P, Robert S, Retornaz K, Garnier JM.
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [Abstract] [Full Text] [Related]

  • 22. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J.
    Ann Intern Med; 1997 Feb 01; 126(3):232-6. PubMed ID: 9027276
    [Abstract] [Full Text] [Related]

  • 23. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P.
    Clin Infect Dis; 1993 Oct 01; 17(4):625-7. PubMed ID: 8268341
    [Abstract] [Full Text] [Related]

  • 24. Treatment of recurrent cutaneous Leishmaniasis.
    Momeni AZ, Aminjavaheri M.
    Int J Dermatol; 1995 Feb 01; 34(2):129-33. PubMed ID: 7737774
    [Abstract] [Full Text] [Related]

  • 25. Pentavalent antimonial-induced torsade de pointes.
    Ortega-Carnicer J, Alcázar R, De la Torre M, Benezet J.
    J Electrocardiol; 1997 Apr 01; 30(2):143-5. PubMed ID: 9141610
    [Abstract] [Full Text] [Related]

  • 26. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
    Hueso M, Bover J, Serón D, Gil-Vernet S, Rufí G, Alsina J, Grinyó JM.
    Nephrol Dial Transplant; 1999 Dec 01; 14(12):2941-3. PubMed ID: 10570102
    [No Abstract] [Full Text] [Related]

  • 27. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ, Aminjavaheri M.
    Eur J Dermatol; 2003 Dec 01; 13(1):40-3. PubMed ID: 12609780
    [Abstract] [Full Text] [Related]

  • 28. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
    Barbosa JF, de Figueiredo SM, Lyon S, Caligiorne RB.
    Curr Clin Pharmacol; 2016 Dec 01; 11(4):265-269. PubMed ID: 27659611
    [Abstract] [Full Text] [Related]

  • 29. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN, Croft SL.
    Trans R Soc Trop Med Hyg; 1993 Dec 01; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T, Lehn N, Landthaler M, Stolz W.
    Dermatology; 2003 Dec 01; 206(3):269-72. PubMed ID: 12673089
    [Abstract] [Full Text] [Related]

  • 31. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Cortés E, Ribera E, Cucurull E, de Otero J, Ocaña I, Pahissa A.
    Med Clin (Barc); 1995 Apr 22; 104(15):578-80. PubMed ID: 7769868
    [Abstract] [Full Text] [Related]

  • 32. Treatment Options for Visceral Leishmaniasis and HIV Coinfection.
    Monge-Maillo B, López-Vélez R.
    AIDS Rev; 2016 Apr 22; 18(1):32-43. PubMed ID: 26936761
    [Abstract] [Full Text] [Related]

  • 33. Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.
    Badaró R, Nascimento C, Carvalho JS, Badaró F, Russo D, Ho JL, Reed SG, Johnson WD, Jones TC.
    Eur J Clin Microbiol Infect Dis; 1994 Apr 22; 13 Suppl 2():S23-8. PubMed ID: 7875148
    [Abstract] [Full Text] [Related]

  • 34. Visceral leishmaniasis in clinical practice.
    Davidson RN.
    J Infect; 1999 Sep 22; 39(2):112-6. PubMed ID: 10609527
    [No Abstract] [Full Text] [Related]

  • 35. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ, Reiszadae MR, Aminjavaheri M.
    Int J Dermatol; 2002 Jul 22; 41(7):441-3. PubMed ID: 12121563
    [Abstract] [Full Text] [Related]

  • 36. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC.
    Trop Med Int Health; 2008 Oct 22; 13(10):1272-6. PubMed ID: 18764817
    [Abstract] [Full Text] [Related]

  • 37. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
    Gasser RA, Magill AJ, Oster CN, Franke ED, Grögl M, Berman JD.
    Clin Infect Dis; 1994 Jan 22; 18(1):83-90. PubMed ID: 7519887
    [Abstract] [Full Text] [Related]

  • 38. Combined antimonial allopurinol therapy in mucosal leishmaniasis.
    Sampaio RN, Marchán EM, Vexenat A, Tristão RJ, Marsden PD.
    Mem Inst Oswaldo Cruz; 1990 Jan 22; 85(3):373-4. PubMed ID: 2134714
    [No Abstract] [Full Text] [Related]

  • 39. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
    Daher EF, Fonseca PP, Gerhard ES, Leitão TM, Silva Júnior GB.
    J Parasitol; 2009 Jun 22; 95(3):652-5. PubMed ID: 19642802
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD, Fleckenstein L, Smith DH.
    Trans R Soc Trop Med Hyg; 1988 Jun 22; 82(1):69-72. PubMed ID: 2845611
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.